Apitolisib

Drug Profile

Apitolisib

Alternative Names: G-038390; G-038390.1; GDC-0980; GDC-0980.1; RG-7422

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech; Piramed
  • Developer Genentech
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Morpholines; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Non-Hodgkin's lymphoma; Prostate cancer; Renal cancer; Solid tumours

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
  • 01 Jun 2015 Genentech completes a phase II trial in Renal cancer (Metastatic disease, Second-line therapy or greater) in USA, France, United Kingdom, Germany and Spain (NCT01442090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top